Extrawell Pharmaceutical Holdings Limited

HKG-0858
Hong Kong Stock Exchange
Healthcare Drug Manufacturers - Specialty & Generic
Global Rank
#34893
Country Rank
#6249
Market Cap
24.35 M
Price
0.0102
Change (%)
3.75%
Volume
2.36 M

Extrawell Pharmaceutical Holdings Limited's latest marketcap:

24.35 M

As of 07/05/2025, Extrawell Pharmaceutical Holdings Limited's market capitalization has reached $24.35 M. According to our data, Extrawell Pharmaceutical Holdings Limited is the 34893th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 24.35 M
Revenue (ttm) 7.06 M
Net Income (ttm) 28.35 M
Shares Out 2.39 B
EPS (ttm) 0.01
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 06/27/2025
Market Cap Chart
Data Updated: 07/05/2025

Extrawell Pharmaceutical Holdings Limited's yearly market capitalization.

Extrawell Pharmaceutical Holdings Limited has seen its market value drop from HK$776.75 M to HK$24.35 M since 2014, representing a total decrease of 96.87% and an annual compound decline rate (CAGR) of 28.07%.
Date Market Cap Change (%) Global Rank
07/05/2025 HK$24.35 M 68% 34893
12/31/2024 HK$119.5 M 47.06% 35771
12/29/2023 HK$81.26 M -56.96% 36944
12/30/2022 HK$188.81 M -14.13% 31594
12/31/2021 HK$219.88 M -28.68% 30957
12/31/2020 HK$308.31 M 81.69% 26018
12/31/2019 HK$169.69 M -33.02% 26041
12/31/2018 HK$253.34 M -50.93% 23244
12/29/2017 HK$516.24 M -18.49% 20130
12/30/2016 HK$633.35 M -28.38% 16909

Company Profile

About Extrawell Pharmaceutical Holdings Limited

Extrawell Pharmaceutical Holdings Limited is an investment holding company specializing in the development, manufacturing, marketing, and distribution of pharmaceutical products. The company primarily operates in the People’s Republic of China and Hong Kong.

Business Segments

  • Manufacturing: Produces pharmaceutical products such as transfer factor oral solution (immune regulator), Wisk (for skin injuries and wound healing), and ZhouBang (thromboxane synthetase inhibitor).
  • Trading: Markets and distributes imported pharmaceuticals, including Skin-Cap (for skin conditions) and Millibar (for hypertension).
  • Gene Development: Engages in genome-related technology development and commercialization.

Key Products

  • Transfer factor oral solution – Treats viral infections and immune deficiencies.
  • Wisk – Addresses skin injuries, burns, and ulcers.
  • ZhouBang – Prevents platelet coagulation and aids blood vessel relaxation.
  • Skin-Cap – Relieves itching, irritation, and skin conditions.
  • Millibar – Manages high blood pressure.

Research & Development

The company is developing an oral insulin product, currently in clinical trials, for diabetes treatment.

Additional Activities

  • Provides agency services.
  • Engages in property investment.

Founded: 1998
Headquarters: Quarry Bay, Hong Kong

Frequently Asked Questions

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.